Alumis (ALMS) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving Alumis (ALMS) right now is Envudeucitinib psoriasis approval path: The lead asset delivered strong Phase 3 skin-clearance results in plaque psoriasis, and management has guided to an NDA filing in the second half of 2026. Product revenue (TTM) is ~$0 (clinical-stage, no approved products). If that keeps playing out, the setup is favourable; the risk to it is as a clinical-stage company, Alumis has essentially no product revenue and burns cash on research and development, so its shares are highly sensitive to trial and regulatory outcomes. No one can predict where ALMS trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Alumis (ALMS) higher?
1. Envudeucitinib psoriasis approval path
The lead asset delivered strong Phase 3 skin-clearance results in plaque psoriasis, and management has guided to an NDA filing in the second half of 2026. Approval and a differentiated safety and efficacy label would be the single biggest driver of the company's value.
2. Pipeline expansion beyond psoriasis
Alumis is testing envudeucitinib in systemic lupus (a Phase 2b readout expected in 2026) and is advancing A-005, a brain-penetrant TYK2 inhibitor for multiple sclerosis. Additional positive readouts would broaden the addressable market and reduce single-asset dependence.
3. Balance sheet and cash runway
The ACELYRIN merger plus the January 2026 raise (about $345 million gross) extended the company's runway across several planned catalysts. A funded balance sheet lowers near-term dilution pressure and buys time to reach approval-stage milestones.
4. Oral convenience versus injectable biologics
As an oral therapy, envudeucitinib competes on convenience against injectable IL-23 and IL-17 biologics that dominate psoriasis. If it pairs biologic-like efficacy with pill dosing, that positioning could support commercial adoption after any approval.
What could weigh on ALMS?
As a clinical-stage company, Alumis has essentially no product revenue and burns cash on research and development, so its shares are highly sensitive to trial and regulatory outcomes. FDA approval is not guaranteed, and even after approval the TYK2 space is competitive, led by Bristol Myers Squibb's already-marketed Sotyktu (deucravacitinib) and other entrants in development. Future equity raises could dilute existing holders, and integration of the ACELYRIN merger adds execution risk. Any single clinical, safety, or commercial disappointment could move the stock sharply, which is characteristic of pre-revenue biotech.
Where ALMS trades today
A forecast starts from where the stock actually is. These are ALMS's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for ALMS as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a ALMS forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the ALMS guide and whether ALMS is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the ALMS outlook
The bottom line: what is driving Alumis (ALMS) is Envudeucitinib psoriasis approval path, with product revenue (ttm) at ~$0 (clinical-stage, no approved products). If that keeps playing out the setup is favourable; the risk is as a clinical-stage company, Alumis has essentially no product revenue and burns cash on research and development, so its shares are highly sensitive to trial and regulatory outcomes. No one can predict the price, so treat any ALMS forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around ALMS with Walnut
Use Alumis as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Alumis (ALMS)?
+
No one can reliably predict where ALMS will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Alumis higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive ALMS higher?
+
The main growth drivers are Envudeucitinib psoriasis approval path; Pipeline expansion beyond psoriasis; Balance sheet and cash runway. Whether they play out is the real question, not a guaranteed path.
What are the risks to ALMS?
+
As a clinical-stage company, Alumis has essentially no product revenue and burns cash on research and development, so its shares are highly sensitive to trial and regulatory outcomes. FDA approval is not guaranteed, and even after approval the TYK2 space is competitive, led by Bristol Myers Squibb's already-marketed Sotyktu (deucravacitinib) and other entrants in development. Future equity raises could dilute existing holders, and integration of the ACELYRIN merger adds execution risk. Any single clinical, safety, or commercial disappointment could move the stock sharply, which is characteristic of pre-revenue biotech.
Will ALMS stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Alumis's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is ALMS a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the ALMS "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.